The ACY3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, engineered to disrupt the endogenous ACY3 gene. This product provides a heterogeneous loss-of-function model for studying ACY3-related biology without the biases of clonal selection. The polyclonal nature ensures a wider representation of knockout events, making it ideal for bulk functional assays and pooled screening approaches.
The host A-549 cell line was originally established from a human lung adenocarcinoma and is a widely used model for non-small cell lung cancer (NSCLC). These cells display characteristics of alveolar type II pneumocytes, including surfactant production and the formation of tight epithelial barriers. A-549 cells are routinely employed to investigate tumor cell proliferation, migration, invasion, and drug responses, providing a physiologically relevant context for examining the role of metabolic enzymes such as ACY3 in lung adenocarcinoma pathophysiology.
ACY3 encodes aspartoacylase-3, a zinc-dependent carboxypeptidase that hydrolyzes the neuropeptide N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate. By modulating extracellular glutamate levels, ACY3 indirectly regulates glutamatergic signaling through ionotropic (NMDA, AMPA) and metabotropic (mGluR) glutamate receptors. Although its upstream regulation is not well characterized, ACY3 may be influenced by amino acid sensing pathways. Functionally, ACY3 interacts with glutamate carboxypeptidase II (GCPII/FOLH1), which also cleaves NAAG, and its activity requires a zinc cofactor. In neural tissues, ACY3-derived NAA supports myelin synthesis, implicating this enzyme in broader cellular signaling cascades and lipid metabolism.
In the A-549 lung adenocarcinoma background, ACY3 knockout disrupts the conversion of NAAG to glutamate and NAA, potentially altering intracellular glutamate pools and downstream signaling. Given the critical role of glutamine and glutamate metabolism in cancer, this knockout model allows dissection of ACY3??s contributions to metabolic reprogramming, redox homeostasis, and nucleotide biosynthesis in NSCLC. Furthermore, because A-549 cells can shape the tumor microenvironment via secreted factors, loss of ACY3 may modify paracrine signaling and stromal interactions, offering a tool to explore how NAAG metabolism intersects with tumor progression and immune evasion.
This polyclonal knockout cell population is suitable for a variety of functional assays, including western blotting and RT-qPCR to confirm gene disruption, glutamate concentration and NAAG hydrolysis activity assays to assess enzymatic function, and cell proliferation, migration, and invasion assays to evaluate phenotypic outcomes. Transcriptomic profiling by RNA-seq can reveal global expression changes upon ACY3 loss. These capabilities make the product valuable for drug target validation and for investigating glutamate-centric metabolic pathways in lung adenocarcinoma. For additional information or technical support, please contact Ascent Research.
